New drug combo aims to tackle tough lung cancer
NCT ID NCT05815173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether adding ladarixin to the standard drug sotorasib can help people with advanced KRAS G12C mutant non-small cell lung cancer. About 40 adults whose cancer has spread or cannot be removed will receive both pills daily. The study will first check for serious side effects, then measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ladarixin and sotorasib
- What this could lead to
- If this combination works, it could offer a new treatment option for people with a specific type of advanced lung cancer that has not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combination may cause serious side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGGarden City, New York, 11530, United States
-
NYU Langone Health
RECRUITINGMineola, New York, 11501, United States
-
NYU Langone Health
RECRUITINGNew Hyde Park, New York, 11042, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10010, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10017, United States